Note

信达生物(01801)宣布与礼来制药(LLY.US)关于达伯舒®的扩大授权许可协议生效,战略合作已通过美国HSR法案等待期

Verified Media
· Views 91
信达生物(01801)宣布与礼来制药(LLY.US)关于达伯舒®的扩大授权许可协议生效,战略合作已通过美国HSR法案等待期 © Reuters. 信达生物(01801)宣布与礼来制药(LLY.US)关于达伯舒®的扩大授权许可协议生效,战略合作已通过美国HSR法案等待期

智通财经APP获悉,10月7日,信达生物(01801)宣布,与礼来制药(LLY.US)签订的扩大关于达伯舒®(信迪利单抗注射液)的全球战略合作已通过美国Hart-Scott-Rodino(“HSR”)法案的等待期。

至此该合作协议的全部条件已具备,交易正式生效。

信达生物与礼来制药将根据合作条款进行必要的授权文件交接工作,礼来制药将向信达生物支付此项合作的两亿美金首付款款项。

此前,信达生物于8月18日发布公告,称其与礼来制药达成关于双方共同在中国开发的抗PD-1单克隆抗体免疫肿瘤药物达伯舒®(信迪利单抗注射液)的扩大授权许可协议。根据该协议条款,礼来将获得达伯舒®在中国以外区域的独家许可,并计划将达伯舒®推向美国和其他地区市场。

Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.

FOLLOWME Trading Community Website: https://www.followme.com

If you like, reward to support.
avatar

Hot

No comment on record. Start new comment.